In less than a month, South Africa will start rolling out the most potent HIV prevention medication the world has seen.
But that alone doesnt guarantee that HIV-negative people who need this twice-a-year injection called lenacapavir LEN will use it.
Uptake and whether LEN contributes to lowering the countrys 170 000 new yearly HIV infections will depend on how the health department approaches those who need it and how accessible the medicine is.
Katherine Gill, a scientist who has researched HIV prevention medication over the past decade and a half, shares nine lessons that could help our LEN roll-out to reach the right people.
Intodays newsletter,Mia Malan introduces us to 9 lessons for South Africas LEN roll-out.Sign up for our newsletter today.
COMMENT
In less than a month, South Africa will start rolling out the most potent HIV prevention medication the world has seen. But that alone doesnt guarantee that HIV-negative people who need this twice-a-year injection called lenacapavir LEN will use it.
